Detroit-based Barbara Ann Karmanos Cancer Institute has become the first cancer center in Michigan to administer a newly approved tumor-infiltrating lymphocyte therapy, lifileucel, to a patient with advanced melanoma.
The one-time treatment, marketed as Amtagvi, was approved by the FDA for adults with unresectable or metastatic melanoma that has progressed despite immune checkpoint inhibitors and, if applicable, BRAF-targeted therapy, according to a Nov. 17 news release from Grand Blanc, Mich.-based McLaren Health Care, of which the Karmanos Cancer Institute is part.
Administration of the therapy requires coordination among Karmanos’ melanoma, stem cell, surgical oncology and pharmacy teams, the release said.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
